Pre-made Mogamulizumab benchmark antibody ( Whole mAb, anti-CCR4 therapeutic antibody, Anti-CKR4/K5-5/CD194/CMKBR4/ChemR13/CC-CKR-4/HGCN:14099 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-354

Pre-Made Mogamulizumab biosimilar, Whole mAb, Anti-CCR4 Antibody: Anti-CKR4/K5-5/CD194/CMKBR4/ChemR13/CC-CKR-4/HGCN:14099 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4).[1] The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL). The latter approval was based on study with 28 subjects.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-354-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Mogamulizumab biosimilar, Whole mAb, Anti-CCR4 Antibody: Anti-CKR4/K5-5/CD194/CMKBR4/ChemR13/CC-CKR-4/HGCN:14099 therapeutic antibody
INN Name Mogamulizumab
TargetCCR4
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesAmgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical
Conditions ApprovedAdult T-cell leukaemia-lymphoma;Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Mycosis fungoides;Sezary syndrome;Mycosis fungoides
Conditions ActiveSpinal cord disorders
Conditions DiscontinuedNon-small cell lung cancer;Asthma;Hypersensitivity;Solid tumours
Development TechPOTELLIGENT Technology